CF102 for the treatment of hepatocellular carcinoma: A phase I/II, open-label, dose-escalation study

Oncologist

Volumn 18, Issue 1, 2013, Pages 25-26

  Stemmer, Salomon M ^a   Benjaminov, Ofer ^a   Medalia, Gal ^a   Ciuraru, Noab B ^a   Silverman, Michael H ^b   Bar Yehuda, Sara ^b   Fishman, Sari ^b   Harpaz, Zivit ^b   Farbstein, Motti ^b   Cohen, Shira ^b   Patoka, Renana ^b   Singer, Barak ^b   Kerns, William D ^b   Fishman, Pnina ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Can Fite BioPharma Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; CF102; SORAFENIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOSINE; ADULT; AGED; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CHILD; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PURINERGIC P1 RECEPTOR AGONISTS; RECEPTOR, ADENOSINE A3; WNT SIGNALING PATHWAY;

EID: 84873044693     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0211     Document Type: Article

References (9)

1. Pinter M, Sieghart W, Graziadei I et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. The Oncologist 2009; 14: 70-76.
2. Pinter M, Sieghart W, Hucke F et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2011; 34: 949-959.
3. Hollebecque A, Cattan S, Romano O et al. Safety and efficacy of sorafenib in hepatocellular carcinoma: The impact of the Child-Pugh score. Aliment Pharmacol Ther 2011; 34: 1193-1201.
4. Cohen S, Stemmer SM, Zozulya G et al. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol 2011; 226: 2438-2447.
5. Fishman P, Bar-Yehuda S, Barer F et al. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 2001; 269: 230-236.
6. Xu Z, Jang Y, Mueller RA et al. IB-MECA and cardioprotection. Cardiovasc Drug Rev 2006; 24: 227-238.
7. Chen GJ, Harvey BK, Shen H et al. Activation of A3 adenosine receptors reduces ischemic brain injury in rodents. J Neurosci Res 2006; 84: 1848-1855.
8. Madi L, Ochaion A, Rath-Wolfson L et al. The A3 adenosine receptor is highly expressed in tumor versus normal cells: Potential target for tumor growth Inhibition. Clin Cancer Res 2004; 10: 4472-4479.
9. Gessi S, Cattabriga E, Avitabile A et al. Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. Clin Cancer Res 2004; 10: 5895-5901.